Aligos Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Aligos Therapeutics

02/11/2022 21:03

* Aligos Therapeutics Inc  ALGS.OQ  reported a quarterly
adjusted
loss of 44 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 58 cents per share.
    * Revenue rose 167.1% to $4.11 million from a year ago;
analysts
expected $750.00 thousand. 
    * Aligos Therapeutics Inc's reported EPS for the quarter was
a
loss of 44 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aligos Therapeutics Inc shares had fallen by 4.5% this
quarter and lost 91.2% so far this year.
    * The company reported a quarterly loss of $18.62 million.
    * Wall Street's median 12-month price target for Aligos
Therapeutics Inc is $2.25 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
2 at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.58          -0.44          Beat
 Jun. 30 2022      -0.67          -0.47          Beat
 Mar. 31 2022      -0.73          -0.84          Missed
 Dec. 31 2021      -0.83          -0.89          Missed